F. Ottou

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.

F. Lacombe, M. Béné, É. Lainey, 2011, Immunology letters.

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

C. Brooks, E. Rowinsky, A. Frankel, 2013 .

Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: The centrifugation step matters!

G. Mourey, P. Saas, E. Racadot, 2012, Thrombosis and Haemostasis.

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

F. Jardin, E. Macintyre, B. Drénou, 2015 .